

February 18-20, 2025 | San Diego, California  
www.lbx-summit.com

FREE TO ATTEND\*  
FOR BIOPHARMA  
& ACADEMIA



9th Annual

# Liquid Biopsy for Precision Oncology Summit

Empower Precision Therapies with Innovative Biopsy Testing

Successfully Integrate Novel Liquid Biopsies into Your Workflows to Rapidly Validate Clinical Biomarkers for Robust Diagnosis, Prognosis & Monitoring Strategies that Significantly Improve Cancer Patient Outcomes

## Expert Speakers Include:



**Rajiv Raja**  
Executive Director,  
Precision Medicine  
Oncology  
**GSK**



**Valerie Mbella**  
Global Director,  
Regulatory Affairs  
**Johnson & Johnson  
Innovative Medicine**



**Anneleen Daemen**  
Executive Director,  
Translational  
Medicine  
**ORIC  
Pharmaceuticals**



**Cynthia Sandoval**  
Senior Director,  
Clinical  
Biomarker  
Development  
**Eli Lilly**



**Marielana Mata**  
Senior Director,  
Clinical Biomarkers  
**Vividion  
Therapeutics**



**Chris Conn**  
Director, Clinical  
Biomarkers &  
Diagnostics,  
Global Diagnostics  
Strategy Lead  
**Amgen**

## 2025 Expertise Partners:



+1 617 455 4188

@ info@hansonwade.com

www.lbx-summit.com

Companion Diagnostics



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

# Welcome to the 9<sup>th</sup> Liquid Biopsy for Precision Oncology Summit

Liquid Biopsy for Precision Oncology Summit  
February 18-20, 2025 | San Diego, California

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

## Why our world-class speakers are getting involved:

From meeting established or new vendors and learning about the latest advances in liquid biopsy research, to reconnecting with colleagues and learning how they have overcome challenges, this meeting has always delivered

**Peter Teriete**,  
Senior Director & Head of Lead Discovery,  
IDEAYA Biosciences

For business development, there's nothing more efficient than networking with the top minds in the industry

**David Westenberg**,  
Managing Director,  
Piper Sandler

From breakthrough early cancer detection tests to better patient monitoring and improved treatment regimens, the liquid biopsy field is poised to redefine the global approach to diagnostics and personalized medicine in the treatment of complex cancers.



















The 9<sup>th</sup> **Liquid Biopsy for Precision Oncology Summit** returns as the world's leading forum for liquid biopsy specialists to share cutting edge data, foster industry connections, and drive advancements in precision medicine for patients with unmet need.

Featuring a dual-tracked agenda dedicated to **Discovery & Technology Innovation** and **Clinical Development & Commercialization**, 30+ world-class speakers will reveal exciting innovations and address critical challenges - enabling you and your team to:

- **Explore a plethora of analytes** including CTCs, RNA and exosomes to enhance disease progression understanding for guided treatment responses
- **Utilize novel bioinformatics tools and improved MRD detection** to refine accuracy and accelerate data readouts of liquid biopsy tests for more precise diagnosis and prognosis
- **Design strategies to translate molecular insights into clinically actionable tools** that can be harnessed to improve patient selection and enable precision monitoring, enabling advanced therapy response assessment
- **Navigate reimbursement and regulatory landscapes** through cross-sector collaborations, expanding commercialization and access to biomarker globally with patients in mind

Join the premier forum for the liquid biopsy community alongside 150+ CEOs, VPs, and Directors of **Liquid Biopsies**, **Translational Biomarkers**, **Precision Oncology**, **Bioinformatics**, and **Companion Diagnostics** to drive progress in precision medicine and transform patient outcomes through networking, learning, and building meaningful partnerships.

## 6 KEY BENEFITS OF ATTENDING

|   |   |  |  |  |   |
|---|---|--|--|--|---|
|   |    |   |   |   |    |
| <b>Pioneer MRD</b> as a clinical endpoint, tackling <b>clinical validity hurdles</b> , to unlock <b>non-invasive testing</b> and more efficacious therapies for patients with unmet needs | <b>Leverage</b> whole-genome and single cell technologies to boost the <b>speed</b> , <b>sensitivity</b> , and <b>specificity</b> of your diagnostics, enabling faster, more <b>accurate diagnoses</b> for personalized treatment options | <b>Optimize</b> your clinical trial design, using liquid biopsies to transform your <b>patient selection strategies</b> and refine your <b>dosage regimes</b> to enhance patient response to precision therapies | <b>Harness</b> untapped analytes, such as <b>RNA and exosomes</b> , to unlock critical insights in drug-diagnostic development that could enhance treatment outcomes       | <b>Streamline</b> reimbursement pathways to drive adoption of liquid biopsies, maximizing the <b>commercial success</b> of your drug-diagnostic and more accessible for patients in need | <b>Overcome</b> regulatory hurdles such as the <b>Final LDT Rule, IVDR</b> , and other global challenges, to fast-track your therapeutic market entry and maximize the impact of your drug for patients |
| <br>                  | <br>  | <br>                                       | <br> | <br>           | <br>                          |

# Agenda at a Glance



Liquid Biopsy for  
Precision Oncology Summit  
February 18-20, 2025 | San Diego, California

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

## Pre-Conference Day Tuesday, February 18

Morning Thought-Leader  
Workshop, Hosted by  
Foundation Medicine



Afternoon Thought  
Leader Engager,  
Hosted by Natera



Evening Thought Leader  
Engager, Hosted by  
Guardant Health



## Conference Day One Wednesday, February 19

Transforming Molecular Insights  
into Actionable Tools to Enable Real  
Time Monitoring of Patients & Drive  
Precision Oncology

### Morning Break & Speed Networking

Defining Robust Clinical Endpoints  
with MRD to Enhance Long-Term  
Survival Prediction & Optimize  
Patient Outcomes

### Networking Lunch

Track A:  
Discovery &  
Technology  
Innovation

Track B:  
Clinical  
Development &  
Commercialization

### Afternoon Networking Break

Track A:  
Discovery &  
Technology  
Innovation

Track B:  
Clinical  
Development &  
Commercialization

End of Conference Day One

## Conference Day Two Thursday, February 20

Navigating Complex Regulatory  
Landscapes to Overcome Global  
Barriers & Achieve Ubiquitous  
Approvals

### Morning Break

Track A:  
Discovery &  
Technology  
Innovation

Track B:  
Clinical  
Development &  
Commercialization

### Networking Lunch

Track A:  
Discovery &  
Technology  
Innovation

Track B:  
Clinical  
Development &  
Commercialization

### Afternoon Networking Break

Enhancing Liquid Biopsy Utilization  
through Strengthened Compliance  
& Strategic Partnerships for Global  
Market Success

End of 9<sup>th</sup> Liquid Biopsy for  
Precision Oncology Summit

# What's New for 2025?

Liquid Biopsy for Precision Oncology Summit  
February 18-20, 2025 | San Diego, California

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



**150+**  
Attendees



**40**  
Brand-New  
Case Studies



**30+**  
World-Class  
Speakers



**8+**  
Hours Of  
In-Person  
Networking



**3**  
Deep Dive  
Interactive  
Panel  
Discussions



**2**  
Dedicated  
Tracks Of  
Content

## 75% of the speaker faculty is new for 2025, including:



**Anneleen Daemen**  
Executive Director,  
Translational Medicine  
**ORIC**  
Pharmaceuticals




**Rajiv Raja**  
Executive Director,  
Precision Medicine  
Oncology  
**GSK**



**Stephen Huang**  
Executive Director,  
Clinical Biomarkers &  
Companion Diagnostics  
**Avenzo Therapeutics**



**Qian Shi**  
Professor of  
Biostatistics & Oncology  
**Mayo Clinic**



**Cynthia Sandoval**  
Senior Director,  
Clinical Biomarker  
Development  
**Eli Lilly**



**Valerie Mbella**  
Global Director,  
Regulatory Affairs  
**Johnson & Johnson**  
Innovative Medicine



**Chris Conn**  
Director, Clinical  
Biomarkers & Diagnostics,  
Global Diagnostics  
Strategy Lead  
**Amgen**



**Greg Opiteck**  
Head, Precision &  
Translational Medicine  
**Affini-T Therapeutics**

## Network with 11 new biotechs, including:



## Address your biggest challenges, such as:

- 🌐 Navigating global regulatory and reimbursement challenges
- 🌐 Exploring novel analytes like circulating cell clusters, exosomes, and more
- 🌐 Advancing bioinformatics and AI applications
- 🌐 Demonstrating the clinical utility of liquid biopsies

## Ample Designated Networking Opportunities with Industry Thought Leaders



With an impressive lineup of new speakers, companies, and attendees, we're introducing an innovative networking format to ensure you connect directly with industry experts

# Your Complete Roadmap to Enhanced Drug Development Through Liquid Biopsy

Liquid Biopsy for Precision Oncology Summit  
February 18-20, 2025 | San Diego, California

Looking to gain deeper insights into your drug diagnostic? Need precise patient selection or monitoring? Aiming to optimize dosage? Facing challenges with IVDR, the Final LDT Rule, or other global regulatory hurdles? Or, seeking pathways for reimbursement or commercialization of your drug-diagnostic?

Look no further, as our faculty of biopharma industry leaders are here to guide you through:

## Discovery



## AI & Bioinformatics



## Standardization



## Dose Optimization



## Patient Selection



## Validation



## Regulation



## Reimbursement



## Commercialization



“I’m thrilled to attend this liquid biopsy meeting, where the potential to transform cancer patient care and advance our field is truly within reach. This gathering offers an invaluable opportunity to explore the latest innovations, connect with leaders dedicated to pioneering solutions, and pave the way for more precise, personalized approaches to cancer treatment that could change countless lives.”

Anneleen Daemen, Executive Director, Translational Medicine, **ORIC Pharmaceuticals**

# Your Expert Speakers



Liquid Biopsy for  
Precision Oncology Summit

February 18-20, 2025 | San Diego, California

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



**Jane Antony**  
Manager - CDx  
**AbbVie**



**Greg Opiteck**  
Head, Precision &  
Translational Medicine  
**Affini-T Therapeutics**



**Chris Conn**  
Director, Clinical  
Biomarkers & Diagnostics,  
Global Diagnostics  
Strategy Lead  
**Amgen**



**Janet Jin**  
Executive Director -  
Precision Medicine,  
Diagnostics & Imaging  
**Amgen**



**Brian Haynes**  
Senior Director, Research  
& Development  
**Asuragen**



**Stephen Huang**  
Executive Director, Clinical  
Biomarkers & Companion  
Diagnostics  
**Avenzo Therapeutics**



**Lauren Leiman**  
Executive Director  
**BLOODPAC**



**Lauren Houghtalin**  
Director, TSS Disease  
State  
**BioIVT**



**David Tsao**  
Co-founder & Chief  
Technology Officer  
**BillionToOne**



**Jeff Gregg**  
Vice President Medical  
Affairs, Biofidelity  
Professor of Pathology &  
Laboratory Medicine  
**University of Nevada  
School of Medicine**



**Gary Pestano**  
Chief Development Officer  
**Biodesix**



**Matthew Pink**  
Vice President - Business  
Development  
**Biodesix**



**Prithwish Pal**  
Director – Global  
Marketing Oncology  
**Bio-Rad**



**Peter Krein**  
Senior Vice President,  
Precision Medicine  
**Boundless Bio**




**Jonathan Baden**  
Executive Director & Head,  
Solid Tumor Oncology  
Diagnostics  
**Bristol Myers Squibb**



**David Spetzler**  
President  
**Caris Life Sciences**



**Julia Elvin**  
Senior Vice President,  
Head of Precision  
Oncology  
**Foundation Medicine**



**Cynthia Sandoval**  
Senior Director, Clinical  
Biomarker Development  
**Eli Lilly**



**Amar Das**  
Vice President -  
Real World Evidence  
**Guardant Health**



**Sarah Shagan**  
Clinical Biomarker Lead  
**Genentech**



**Rajiv Raja**  
Executive Director,  
Precision Medicine  
Oncology  
**GSK**



**Emily Finnegan**  
Director, Global Regulatory  
Affairs, PMDH  
**GSK**



**Ekaterina Gracheva**  
Epigenomics Application  
Specialist  
**Hologic Diagenode**



**Peter Teriete**  
Senior Director & Head,  
Lead Discovery  
**IDEAYA Biosciences**



**Fernando Cruz-Guilloty**  
Director - Oncology  
Precision Medicine &  
Diagnostics Lead  
**Johnson & Johnson**



**Paul Krzyzanowski**  
Medical Director, Precision  
Medicine  
**Johnson & Johnson**



**Valerie Mbella**  
Global Director,  
Regulatory Affairs  
**Johnson & Johnson  
Innovative Medicine**



+1 617 455 4188

@ info@hansonwade.com



www.lbx-summit.com



Companion Diagnostics



# Your Expert Speakers



Liquid Biopsy for  
Precision Oncology Summit

February 18-20, 2025 | San Diego, California

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



**David Weingeist**  
Scientific Director,  
Oncology Diagnostics  
Leader  
**Johnson & Johnson  
Innovative Medicine**



**Erin Newburn**  
Senior Director, Field  
Applications Scientist  
**Labcorp**



**Joe McDermott**  
Bioinformatics Lead  
**Lantern Pharma**



**Qian Shi**  
Professor of Biostatistics  
& Oncology  
**Mayo Clinic**



**John Simmons**  
Global Vice President,  
Biopharma  
**Natera**



**Robert Feeney**  
Director Account Solutions,  
Personalized & Precision  
Medicine  
**Novartis**



**Anneleen Daemen**  
Executive Director,  
Translational Medicine  
& Head of Bioinformatics,  
**ORIC Pharmaceuticals**



**Ryan Mathis**  
Vice President of Market  
Access & Business  
Development  
**Oxford BioDynamics**



**Kate Cunningham**  
Field Applications Scientist  
**Personalis**



**Jean-Francois Martini**  
Executive Director,  
Translational Oncology  
Lead, Global Product  
Development, Oncology  
**Pfizer**



**Paul Hofman**  
Professor of Pathology  
**University Côte d'Azur**



**David Westenberg**  
Managing Director,  
Equity Research  
**Piper Sandler**



**Lisa Boersma**  
Associate Director,  
Precision Medicine &  
Companion Diagnostic  
**Regeneron**



**Deepa Parthasarathy**  
Director & Head,  
Biomarker Operations  
**Repare Therapeutics**



**Erik Goka**  
Vice President - Biology &  
Precision Medicine  
**Revere Pharmaceuticals**



**Hugh Wang**  
Director, Bioinformatics  
**Summit Therapeutics**



**Ezra Cohen**  
Chief Medical Officer -  
Oncology  
**Tempus**



**Holger Neecke**  
Chief Executive Officer  
**Tethis**



**Frédéric Wuilque**  
Product Life Cycle  
Manager - Oncology  
**Volition**



**Marielana Mata**  
Senior Director, Clinical  
Biomarkers  
**Vividion Therapeutics**



**Carolina Reduzzi**  
Director, Liquid Biopsy  
Platform, Assistant  
Professor of Cancer  
Biology Research in  
Medicine  
**Weill Cornell Medicine**



**Olivier Harismendy**  
Vice President,  
Translational Data Science  
& Computational Biology  
**Zentalis Pharmaceuticals**

Extremely convenient and well organized with cutting edge material, speakers and organizations

**Past Attendee**, Director - Principal Scientist, Bioinformatics,  
**Cardiff Oncology**

7

+1 617 455 4188 @ info@hansonwade.com

www.lbx-summit.com Companion Diagnostics

hansonwade

# Conference Day One

## Wednesday, February 19, 2025



7.00 Registration & Light Breakfast



**Peter Krein**  
Senior Vice President,  
Precision Medicine  
Boundless Bio

7.50 Chair's Opening Remarks

### Transforming Molecular Insights into Actionable Tools to Enable Real Time Monitoring of Patients & Drive Precision Oncology



**Erik Goka**  
Vice President -  
Biology & Precision  
Medicine  
Revere  
Pharmaceuticals

8.00 Liquid Biopsies in Precision Oncology: Bench to Bedside & Beyond

- Overview of liquid biopsy analytes
- How liquid biopsies are currently shaping patient care and treatment decision-making
- What will it take to accelerate integration into routine clinical practice?



**Julia Elvin**  
Senior Vice President,  
Head of Precision  
Oncology  
Foundation Medicine

8.30 Unveiling Blind Spots: How CH Prediction Can Transform Biomarker Strategies

- Unmask Critical Challenges in CH Prediction: Discover how blind spots in conventional diagnostic approaches to clonal hematopoiesis (CH) can lead to misinterpretation, missed signals, and trial delays
- Case Study Insights That Redefine Precision: Dive into a real-world case study showcasing how Foundation Medicine's advanced tools predict and differentiate CH, delivering actionable insights that can strengthen trial design
- Accelerate Your Path to Market: See how addressing CH complexities can empower biopharma teams to optimize timelines, reduce risks, and advance therapies to patients with greater confidence



**Qian Shi**  
Professor of  
Biostatistics &  
Oncology  
Mayo Clinic

9.00 Pioneering Liquid Biopsies with MRD in Oncology for Accelerated Approval in Multiple Myeloma

- Understanding the significance of MRD as a key treatment response indicator in multiple myeloma
- Demonstrating the evidence of MRD negativity predicting long-term survival
- Pioneering novel approvals for MRD as clinical endpoints



**Amar Das**  
Vice President -  
Real World Evidence  
Guardant Health

9.30 Leveraging Real-World Data to Drive Decision Making: GuardantINFORM's Impact on Drug Development

- Demonstrating the strategic application of GuardantINFORM's clinic-genomic data across each phase of drug development
- Showcasing how GuardantINFORM's methylation data & novel epigenomic insights complement existing biomarker strategies
- Introducing Guardant's exciting partnerships with ConcertAI and COTA, illustrating the power of integrating EHR data with clinic-genomic data



10.00 Morning Break & Speed Networking

As the Clinical Biomarkers and Liquid Biopsy community unite once more, this valuable session will ensure that you can connect with your peers in the room to make new and lasting connections. All attendees will have the opportunity to meet and network with their industry peers.

### Defining Robust Clinical Endpoints with Liquid Biopsies to Enhance Long-Term Survival Prediction & Optimize Patient Outcomes



**John Simmons**  
Global Vice President  
Biopharma  
Natera

11.00 Session Reserved for Natera



# Conference Day One

## Wednesday, February 19, 2025

### 11.30 Forging Pathways to Equitable Precision Medicine by Ensuring Universal Access to Liquid Biopsies & MRD Detection




- Discussing how liquid biopsies can reduce disparities in early cancer detection and monitoring, improving outcomes for underserved and underrepresented communities globally
- Evaluating how current strategies are working to ensure equal access to liquid biopsies and MRD detection, regardless of socioeconomic status
- Analyzing the impact of MRD as an objective measure, irrespective of gender or ethnicity, to affordably diagnose patients


Moderated by:

|   |   |  |  |  |
|---|---|--|--|--|
|  <p><b>Peter Krein</b><br/>Senior Vice President, Precision Medicine<br/><b>Boundless Bio</b></p> |  <p><b>Qian Shi</b><br/>Professor of Biostatistics &amp; Oncology<br/><b>Mayo Clinic</b></p> |  <p><b>Greg Opiteck</b><br/>Head, Precision &amp; Translational Medicine<br/><b>Affini-T Therapeutics</b></p> |  <p><b>Rajiv Raja</b><br/>Executive Director, Precision Medicine Oncology<br/><b>GSK</b></p> |  <p><b>Robert Feeny</b><br/>Director Account Solutions, Personalized &amp; Precision Medicine<br/><b>Novartis</b></p> |
|---|---|--|--|--|


### 12.00 Derisk & Explore with the Comprehensive Power of Caris Life Sciences' Assure Liquid Biopsy Platform

|  |   |
|--|---|
|  <p><b>David Spetzler</b><br/>President<br/><b>Caris Life Sciences</b></p> | <ul style="list-style-type: none"> <li>• Integrated molecular profiling platform designed to accelerate and de-risk biopharma therapeutic development while enhancing the precision and reliability of clinical trials</li> <li>• Critical analysis of buffy coat to provide precise insights into clonal hematopoiesis (CH) and the impact of germline mutations on therapeutic response and patient stratification</li> <li>• Expanding the range of Assure solutions spanning the entire cancer continuum, enabling advanced molecular insights</li> </ul> |
|--|---|

### 12.30 Integrating Liquid Biopsies into Clinical Workflows to Enhance Decision Making in Clinical Trials

|   |   |
|---|---|
|  <p><b>Jonathan Baden</b><br/>Executive Director, Head of Solid Tumor Oncology Diagnostics<br/><b>Bristol Myers Squibb</b></p> | <ul style="list-style-type: none"> <li>• Leveraging ctDNA to provide continuous insights into micro-tumor environments</li> <li>• Accurately validating the clinical utility of liquid biopsy tests to improve decision making</li> <li>• Enhancing drug-development pipelines with real-time patient monitoring for improved patient treatment and personalized therapy adjustments</li> </ul> |
|---|---|

### 1.00 Enhancing Precision Oncology with Liquid Biopsy Insights

|  |   |
|--|---|
|  <p><b>Ezra Cohen</b><br/>Chief Medical Officer - Oncology<br/><b>Tempus</b></p> | <ul style="list-style-type: none"> <li>• Discover the transformative impact of liquid biopsy (LBx) in oncology, supporting therapy selection and real-time monitoring of disease progression</li> <li>• Learn about Tempus AI's comprehensive LBx portfolio, designed to detect actionable tumor signals, help monitor treatment outcomes, and derive new care insights</li> <li>• Explore the integration of assays and AI-augmented platforms by Tempus, helping to enhance patient management and improve clinical outcomes</li> </ul> |
|--|---|



### 1.30 Networking Lunch

|   |   |
|---|---|
| <p><b>Track A:</b><br/><b>Discovery &amp; Technology Innovation</b><br/>Chair: <b>Janet Jin</b>, Executive Director - Precision Medicine, Diagnostics &amp; Imaging, <b>Amgen</b></p> | <p><b>Track B:</b><br/><b>Clinical Development &amp; Commercialization</b><br/>Chair: <b>Greg Opiteck</b>, Head, Precision &amp; Translational Medicine, <b>Affini-T Therapeutics</b></p> |
|---|---|

|   |   |
|---|---|
| <p><b>Enhancing Predictive Biomarkers through Multi-Omics &amp; Advanced Analyte Detection for Refined Patient Selection Strategies</b></p> | <p><b>Leveraging Liquid Biopsies to Optimize Clinical Trial Design for Better Dosage Regimes &amp; Enhanced Patient Selection</b></p> |
|---|---|

|  |   |
|--|---|
| <p><b>2.30 Building Robust Bioinformatics Pipelines for Liquid Biopsy Data to Enhance Precision Outcomes</b></p> <ul style="list-style-type: none"> <li>• Demonstrating methods to normalize heterogeneous liquid biopsy data from various providers to achieve consistent analysis</li> <li>• Leveraging machine learning to enhance liquid biopsy data accuracy, aligning closer to tissue biopsy standards</li> </ul> <p><b>Joe McDermott</b>, Bioinformatics Lead, <b>Lantern Pharma</b></p> | <p><b>2.30 Redefining Patient Selection Strategies with Liquid Biopsies to Revolutionize Patient Safety in Clinical Trials</b></p> <ul style="list-style-type: none"> <li>• Harnessing ctDNA to provide novel biomarker insights for improved patient selection</li> <li>• Integrating molecular insights into patient selection strategies</li> <li>• Understanding the commercial advantages of improved patient selection</li> </ul> <p><b>Sarah Shagan</b>, Clinical Biomarker Lead, <b>Genentech</b></p> |
|--|---|

# Conference Day One

## Wednesday, February 19, 2025

### 3.00 ESR1 & Beyond: Leveraging Exosomes for Highly Sensitive LBx Solutions

- Exosomes enable more complete and sensitive disease detection than cfDNA alone with unparalleled sensitivity (<0.1%VAF) to detect ESR1 mutations on widely available instruments
- The QuantideX® qPCR ESR1 exoMutation Kit (RUO) combines co-enrichment of ctDNA and exosomal RNA, qPCR reagents, and automated push-button software for a complete LBx solution for clinical research laboratories everywhere

**Brian Haynes**, Senior Director, Research & Development, **Asuragen**

### 3.30 Panel Discussion: Improving MRD Detection & Leveraging Multi-omics to Refine Predictive Biomarkers for Augmented Treatment Strategies

- Investigating how advanced MRD detection methods are being used to refine the identification of biomarkers of treatment response
- Exploring the impact of multi-omics on biomarker detection
- What sensitivity is sufficient to reliably identify predictive biomarkers?
- How to ensure regulatory guidelines are adhered to whilst leveraging novel technology

**Moderated by: Janet Jin**, Executive Director - Precision Medicine, Diagnostics & Imaging, **Amgen**

**Jean-Francois Martini**, Executive Director, Translational Oncology Lead, Global Product Development, Oncology, **Pfizer**

**Peter Krein**, Senior Vice President, Precision Medicine, **Boundless Bio**

**Hugh Wang**, Director, Bioinformatics, **Summit Therapeutics**

### 3.00 Ultra-Sensitive MRD Utilization to Overcome Challenges in Early-Stage Cancer Recurrence Detection

- NeXT Personal is an advanced tumor-informed liquid biopsy assay with ultra-sensitive detection down to 1PPM
- Ultrasensitive detection with this bespoke whole genome sequencing based assay improves detection of ctDNA at baseline and during follow-up with increased lead time over clinical relapse
- Clinical studies in early-stage lung and breast cancer establish that NeXT Personal MRD detection is strongly correlated with patient outcome

**Kate Cunningham**, Field Applications Scientist, **Personalis**

### 3.30 Panel Discussion: Harnessing MRD & ctDNA to Inform Clinical Trial Decision Making & Improve Dosage Regimens

- How to integrate MRD into clinical trial designs to tailor dosage regimes more precisely
- Leveraging MRD insights to refine dosage escalation and de-escalation protocols for optimal efficacy and safety
- How to use MRD data to adjust treatment strategies and inform Standard of Care protocols

**Moderated by: Matthew Pink**, Vice President - Business Development, **Biodesix**

**Chris Conn**, Director, Clinical Biomarkers & Diagnostics, Global Diagnostics Strategy Lead, **Amgen**

**Marielena Mata**, Senior Director, Clinical Biomarkers, **Vividion Therapeutics**

**Stephen Huang**, Executive Director, Clinical Biomarkers & Companion Diagnostics, **Avenzo Therapeutics**

### 4.00 Empowering Precision Oncology & MRD Monitoring through ctDNA & CTC Analysis

- Leveraging Droplet Digital (ddPCR) to develop novel multiplexed assays for therapy selection and MRD monitoring
- Potential for incorporating ddPCR in MRD clinical trials
- Enrichment and molecular profiling of CTCs for biomarker discovery

**Gary Pestano**, Chief Development Officer, **Biodesix**

**Prithwish Pal**, Director – Global Marketing Oncology, **Bio-Rad**

### 4.00 Evaluation of Liquid Biopsy NGS Assay Kits to Improve Access to Rapid, Decentralized Biomarker Testing for NSCLC in Daily Practice

- Access to cost effective, easy to use, distributed NGS kits for liquid biopsy testing (LBx) are critical to helping support more rapid treatment decision making for cancer patients. These kit-based methods allow a broad range of laboratories to perform high-quality NGS testing, which improves patient access to targeted therapies in a short turnaround time
- Kitted LBx assays can typically be categorized into either amplicon-based targeted panels or hybrid capture based CGP assays, with varying costs, NGS workflows, including automation of different steps and resulting genomic content
- A summary of our evaluation on site of multiple NGS-based LBx products, review their features and benefits and discuss how they might be used clinically to help more effectively and rapidly genomically profile patients for a better care in advanced NSCLC

**Paul Hofman**, Professor of Pathology, **University Côte d'Azur**



4.30 Afternoon Networking Break

# Conference Day One

## Wednesday, February 19, 2025

### Innovating Liquid Biopsy Strategies to Decode Tumor Complexity & Enhance Oncology Insights for Better Cancer Treatments

#### 5.00 Uncovering the Role of Circulating Cancer Cell Clusters in Metastasis & Therapeutic Targeting: A Novel Approach in Liquid Biopsy

- Circulating metastatic cancer cell clusters (MCCs) provide one of the worst prognoses for cancer patients
- Routine and efficient capture of MCCs is essential for diagnostic, prognostic, and therapeutic approaches
- Anti-metastatic drugs targeting MCCs independent of treatment against primary tumours are going to bring significant benefit to survival and quality of life to nearly all cancer patients

**Peter Teriete**, Senior Director & Head of Lead Discovery, IDEAYA Biosciences

#### 5.30 Panel Discussion: Pre-Analytical Insights to Enhance Liquid Biopsy Development Success

- Ensure compliance with evolving global standards to future-proof your studies
- Optimize pre-analytical protocols to generate consistent, high-quality results that drive impactful discoveries
- Ensure your assays capture the right analytes with precision, leading to better clinical outcomes

**Moderated by: Lauren Houghtalin**, Director, TSS Disease State, BioIVT

**Chris Conn**, Director, Clinical Biomarkers & Diagnostics, Global Diagnostics Strategy Lead, Amgen

**Jean-Francois Martini**, Executive Director, Translational Oncology Lead, Global Product Development, Oncology, Pfizer

**Cynthia Sandoval**, Senior Director, Clinical Biomarker Development, Eli Lilly

**Julia Elvin**, Senior Vice President, Head of Precision Oncology, Foundation Medicine

6.00 Chair's Closing Remarks

### Streamlining Liquid Biopsy Operations & Advancing Biomarker Analysis to Promote Routine Use of Liquid Biopsies in Clinical Settings

#### 5.00 Optimizing Clinical Biomarker Operations in Liquid Biopsy Trials: Streamlining Sample Collection to Analysis

- Ensuring sample integrity from collection to analysis to power reliable biomarker data
- Navigating patient timing, shipments, and lab workflows for streamlined trial operations
- Uncovering ctDNA profile shifts across dosing to drive impactful clinical outcomes

**Deepa Parthasarathy**, Director & Head, Biomarker Operations, Repare Therapeutics

#### 5.30 Multi-Analytes Analysis in Prostate Cancer: Overcoming Tumor Heterogeneity Challenges with Liquid Biopsy

- Impact of tumor heterogeneity on drug development and patient selection
- Advantages of a multi-analyte biomarker approach in a phase 1 trial
- Opportunity, and challenges, of precision medicine for prostate cancer

**Anneleen Daemen**, Executive Director, Translational Medicine & Head of Bioinformatics, ORIC Pharmaceuticals

6.00 Chair's Closing Remarks

6.05 End of Conference Day One

6.15 Networking Drinks Reception in Partnership with Guardant Health



# Conference Day Two

## Thursday, February 20, 2025



8.00 Light Breakfast & Morning Networking



**Valerie Mbella**  
Global Director,  
Regulatory Affairs  
**Johnson & Johnson**  
Innovative Medicine

8.50 Chair's Opening Remarks

### Navigating Complex Regulatory Landscapes to Overcome Global Barriers & Achieve Ubiquitous Approvals



**Lisa Boersma**  
Associate Director,  
Precision Medicine &  
Companion Diagnostics  
**Regeneron**

9.00 Navigating Regulatory Lab Quality for Liquid Biopsies to Adhere to IVDR Compliance

- Navigating complex lab compliance with IVDR and emerging LDT regulations to streamline global market access
- Implementing rigorous audit protocols that reveal hidden compliance gaps overlooked by standard inspections
- Developing robust criteria to evaluate lab partners, ensuring top-tier quality for every step of the liquid biopsy process

9.30 **Panel Discussion: Balancing Innovation & Compliance in Diagnostic Testing Amidst the Final LDT Rule to Ensure Patient Access to Great Drugs**



- Debating the positive and negative aspects of the Final LDT Rule for liquid biopsy innovation
- Understanding the responsibilities for drug-diagnostic partnerships in ensuring swift approvals
- How can we minimize financial and temporal burdens of complex approvals in the US?

Moderated by:



**Valerie Mbella**  
Global Director, Regulatory Affairs  
**Johnson & Johnson Innovative**  
Medicine



**Chris Conn**  
Director, Clinical Biomarkers &  
Diagnostics, Global Diagnostics  
Strategy Lead  
**Amgen**



**Emily Finnegan**  
Director, Global Regulatory  
Affairs, PMDH  
**GSK**



**Erin Newburn**  
Senior Director, Field  
Applications Scientist  
**Labcorp**

10.00 Navigating Challenges in Utilizing ctDNA Profiling for Biomarker-Driven Therapy Development

- ctDNA profiling is applicable throughout the drug development and patient journeys
- Innovative ctDNA profiling approaches are enhancing sensitivity and accuracy
- A globalized approach is needed in today's precision oncology landscape



10.30 Morning Networking Break

#### Track A: Discovery & Technology Innovation

Chair: **David Weingeist**, Scientific Director, Oncology Diagnostics Leader, **Johnson & Johnson Innovative Medicine**

#### Track B: Clinical Development & Commercialization

Chair: **Lauren Leiman**, Executive Director, **BLOODPAC**

#### Harnessing Multi-Analytes to Advance Comprehensive Oncology Understanding to Unlock Deeper Insights into Patient Surveillance

#### Overcoming Reimbursement Barriers to Enhance Patient Access to Innovative Therapies

11.30 **ctDNA & the Era of Liquid Biopsies: Overlaying Novel Diagnostic Lenses to Overcome Challenges in Precision Medicine**

- Historical perspectives and the promise of liquid biopsies
- The utility and use cases in clinical trial strategies; shared learning and synergies to accelerate drug development
- Amplifying the impact of liquid biopsies in precision oncology, and future considerations

**Jane Antony**, Manager - CDx, **AbbVie**

11.30 **Bridging the Gap with Strategies for Achieving Consistent Reimbursement of Liquid Biopsies Across Global Markets**

- Examining the varying reimbursement policies for liquid biopsies in different regions and their impact on clinical adoption
- Engaging with payers and healthcare regulators to align on coverage requirements
- Outlining approaches for generating robust health-economic evidence to support reimbursement application

**Paul Krzyzanowski**, Medical Director, Precision Medicine, **Johnson & Johnson Innovative Medicine**

# Conference Day Two

## Thursday, February 20, 2025

### 12.00 Recombinant Nucleosome Quality Control Materials for ctDNA Molecular Profiling: Control from Sample, DNA Extraction, Library Prep, Sequencing to Data Analysis

- Quality control is an essential step in any NGS workflow; allowing the integrity and quality of data to be checked before analysis and interpretation. Currently, there is not a standardised method nor material to control the whole workflow, from blood collection to bioinformatic analysis
- Volition has developed a unique reference material made of recombinant nucleosomes in plasma. The advantage of using recombinant nucleosome is that the cfDNA will be analyzed in its native nucleosomal format, whereas existing reference materials are only composed of DNA
- Those recombinant nucleosomes can be processed in parallel to patient samples, from DNA extraction to final results. It can address any kind of genomic alteration at any Mutated Allelic Fraction

**Frédéric Wuilque**, Product Life Cycle Manager - Oncology, Volition

### 12.00 Optimizing Tissue-free ctDNA Evaluations with QCT Technology: Enhancing Sensitivity for Therapy Selection & Enabling Quantitative Therapy Response Monitoring

- Employing our patented QCT technology to achieve single molecule resolution
- Enhanced limit of detection augments sensitivity in low-VAf setting to improve detection of clinically actionable alterations
- Precise therapy Response quantification and clonal profiling through a personalized methylation-based approach

**David Tsao**, Co-Founder & Chief Technology Officer, BillionToOne

### 12.10 Panel Discussion: Unleashing the Power of CTCs to Revolutionize Biomarker Discovery & Transform Cancer Insights

- How are CTCs currently being utilized to shape precision medicine approaches?
- Exploring the power of exosomes in early cancer diagnostics to improve accuracy in tumor representation
- Leveraging alternative biological fluids to enhance the detection of complementary biomarkers

**Moderated by: Holger Neecke**, Chief Executive Officer, Tethis  
**Carolina Reduzzi**, Director, Liquid Biopsy Platform, Assistant Professor of Cancer Biology Research in Medicine, Weill Cornell Medicine

**Jane Antony**, Manager - CDx, AbbVie

**Fernando Cruz-Guilloty**, Director - Oncology Precision Medicine & Diagnostics Lead, Johnson & Johnson

### 12.10 Predicting Oncology Market Trends Over the Next Five Years

- Therapy Selection: Continued strong adoption
- MRD: The next big wave of growth
- Screening: The eventual future

**David Westenberg**, Managing Director, Equity Research, Piper Sandler



### 12.40 Networking Lunch

### Optimizing Biomarker Discovery with Unparalleled Liquid Biopsy Analysis to Enhance Therapeutic Efficacy in Clinical Trials

#### 1.40 Revolutionizing Early Bladder Cancer Detection with Urine-Based Genomic Liquid Biopsies

- Utilizing urine samples for patient screening, providing a reliable and patient-friendly alternative that addresses the challenges associated with tissue and plasma-based testing
- Employing a highly sensitive genomic method capable of identifying a broad spectrum of genetic alterations
- Leveraging the robust detection capabilities of urine-based assays to facilitate earlier diagnosis and more personalized treatment strategies

**David Weingeist**, Scientific Director, Oncology Diagnostics Leader, Johnson & Johnson Innovative Medicine

### Accelerating Liquid Biopsy Adoption through Optimal Implementation & Commercialization to Maximize Clinical Impact & Patient Access

#### 1.40 Enhancing Collaboration & Harmonization in Liquid Biopsy Surveillance: A BLOODPAC Perspective

- Highlighting key strategies to foster collaboration among stakeholders in liquid biopsy research
- Introducing the new lexicon designed to standardize terminology and practices across the liquid biopsy field

**Lauren Leiman**, Executive Director, BLOODPAC

# Conference Day Two

## Thursday, February 20, 2025

### 2.10 Combining Liquid Biopsy & DNA Methylation to Advance Cancer Biomarker Discovery: Technologies & Case Studies

- Epigenomics adds an additional layer of information beyond standard genomics, offering deeper insights
- Liquid biopsies are easy and non-invasive tools, but they require precise techniques and analysis to achieve optimal results
- By utilizing DNA methylation analyses on liquid biopsies, we can identify and validate biomarker signatures for early detection and monitoring of minimal residual disease (MRD) within clinical cohorts

**Ekaterina Gracheva**, Epigenomics Application Specialist, Hologic Diagenode

### 2.10 When Samples Fail, Aspyre Lung Prevails: Rapid, Highly Sensitive RNA/DNA Detection for Challenging Tissue Biopsies & Low VAF Liquid Biopsies in NSCLC Trials

- Understand how Aspyre rescues samples not amenable for NGS
- Learn how Aspyre achieves exquisite performance with all sample types including FFPE, FNA washes, pleural effusions, liquid biopsy
- Harness the power of Aspyre to receive results within 2 days
- Optimize patient enrollment by testing both RNA and DNA in a single test

**Jeff Gregg**, Vice President Medical Affairs, Biofidelity, Professor of Pathology & Laboratory Medicine, University of Nevada School of Medicine



2.25 Afternoon Networking Break



2.40 Afternoon Networking Break

## Enhancing Liquid Biopsy Utilization through Strengthened Compliance & Strategic Partnerships for Global Market Success



**Olivier Harismendy**  
Vice President,  
Translational  
Data Science &  
Computational Biology  
**Zentalis**  
Pharmaceuticals

### 3.10 Molecular Response in Ovarian Cancer

- Reviewing available methodologies and published studies
- Presenting a Case Review from published studies
- Showcasing lessons learnt from azenosertib clinical studies



**Ryan Mathis**  
Vice President of  
Market Access &  
Business Development  
**Oxford BioDynamics**

### 3.40 Predictive, Prognostic & Diagnostic Biomarkers in Oncology

- EpiSwitch® 3D Genomic biomarker platform and data knowledge
- EpiSwitch Colorectal Test: from polyps to early cancer stages
- EpiSwitch Multi-Choice Cancer Detection: lymphomas, sarcomas and melanomas



**Cynthia Sandoval**  
Senior Director,  
Clinical Biomarker  
Development  
**Eli Lilly**

### 4.10 Driving Innovation through Strategic Vendor Partnerships in Precision Medicine Development for Global Success

- How to establish specific, measurable goals for partnerships to ensure alignment and drive focus on shared outcomes
- How to identify and utilize the unique strengths of each partner to create synergistic solutions that accelerate development timeline
- Maintaining flexibility in adjusting strategies based on emerging liquid biopsy findings to ensure rapid responses and capitalize on new opportunities in precision medicine



**Valerie Mbella**  
Global Director,  
Regulatory Affairs  
**Johnson & Johnson**  
Innovative Medicine

### 4.40 Chair's Closing Remarks

### 4.45 End of 9<sup>th</sup> Liquid Biopsy for Precision Oncology Summit

# Pre-Conference Day

## Tuesday, February 18, 2025



Liquid Biopsy for  
Precision Oncology Summit

February 18-20, 2025 | San Diego, California

Register your Interest Here\*

\*Attendance at these sessions is subject to availability and partner approval

Join senior executives from leading biopharma and liquid biopsy innovators in an exclusive, invitation-only day, designed to ignite the future of precision medicine. Take advantage of this rare opportunity to engage in interactive, high-stakes discussions, where cutting-edge advancements and breakthrough technologies are set to reshape the landscape of liquid biopsies and personalized care.

Prepare to delve into intimate, closed-door conversations with industry trailblazers, influencing global liquid biopsy strategies and accelerating the path to faster and more effective treatments for patients in need.

### Morning Thought-Leader Workshop

10.15am - 2.00pm

#### What's Hidden Could Change Everything

Hidden blind spots in diagnostic testing could be stalling your biomarker strategies, delaying trials, and risking regulatory approval. Join this workshop to uncover critical gaps that others miss, tackle the complexity of evolving regulatory demands, and gain actionable insights to move your drug development forward. Discover how Foundation Medicine's innovative approach empowers biopharma teams to accelerate timelines, optimize trial outcomes, and bring life-changing therapies to market with confidence. Uncover what's hidden. Transform what's possible. Join us to learn more.



FOUNDATION  
MEDICINE

### Afternoon Thought Leadership Engager

2.45pm - 5.00pm

#### Towards ctDNA MRD as a CDx & a Surrogate Endpoint: Real-Life Implementation & Operationalization

- Review insights from recent clinical trials and publications to inform strategies for ctDNA-driven drug development and trial design
- Discuss key factors supporting successful incorporation of MRD into global clinical trials for patient stratification, enrichment, and early response endpoint
- Discuss regulatory considerations for global clinical trial use and companion diagnostics (CDx) development
- Explore how Natera Oncology's newly launched portfolio of diagnostics products and clinical trial services can potentially accelerate ctDNA-guided clinical development



### Evening Thought Leadership Engager

5.45pm - 8.15pm

#### Shaping the Next-Generation of Cancer Therapeutics with Novel Epigenomic Biomarkers

BioPharma companies are at the forefront of developing new therapies in a highly competitive precision oncology environment. To develop novel cancer therapeutics, BioPharma needs to identify novel biomarkers to develop more precise treatment options. Leveraging epigenomics with liquid biopsy can drive new insights to deliver/produce more stringent patient selection criteria and more precise treatment options



Register Your Interest to Attend & Take Part in Key Discussions & Decisions that will Shape the Liquid Biopsy Industry Going Forward\*

\*Attendance at these sessions is subject to availability and partner approval

# 2025 Partners

Liquid Biopsy for Precision Oncology Summit  
February 18-20, 2025 | San Diego, California

## Expertise Partners



## Program Partners




## Spotlight Partners



## Panel Partners




## Exhibition Partners



## Meeting Partners



## GET INVOLVED



Sam Sarwar  
Senior Commercial Director, BDx Events  
& Market Research  
+1 617 455 4188  
sponsor@hansonwade.com



# Partner With Us

## Partner with the World's Leading Liquid Biopsy Forum

The **9<sup>th</sup> Liquid Biopsy for Precision Oncology Summit** provides a comprehensive, end-to-end perspective on liquid biopsy-enhanced drug trials, and is the ideal platform to showcase your solutions to ensure brand visibility. Our audience of over 150 decision-makers from leading biopharma are actively seeking partnerships with innovative service and solution providers with capabilities in assay development, diagnostics, AI, and bioinformatic solutions to help them drive precision oncology forward.



### Showcase Your Pioneering Solutions

Present your cutting-edge technologies and diagnostic services to a focused audience of senior precision medicine experts. With strategic exposure pre- and post-conference, differentiate your offerings from your competitors, and seize branding opportunities to amplify your visibility and cement your position as a leader in advancing cancer care through precision medicine.



### Gain Strategic Market Insights



Stay ahead in the evolving and competitive liquid biopsy landscape. Understand key priorities for biopharma and precision medicine leaders seeking innovative tools to improve MRD detection, real-time monitoring, and patient outcomes. Position your solutions to meet the latest regulatory demands and scientific standards in this critical field.




### Forge High-Impact Collaborations

Engage with influential stakeholders from biopharma, diagnostics, and academic institutions within the liquid biopsy field. Dedicated intimate networking sessions, including speed networking and targeted discussions, foster unparalleled opportunities to create partnerships that drive progress in cancer diagnostics and patient care, with a shared goal of expanding precision oncology access.

## SENIORITY OF ATTENDEES\*



## TYPES OF COMPANIES ATTENDING\*



\*Based on the 8th Liquid Biopsy for Precision Oncology Summit

## GET INVOLVED



**Sam Sarwar**  
Senior Commercial Director, BDx Events & Market Research  
+1 617 455 4188  
sponsor@hansonwade.com

# Ready to Register?

## 3 Easy Ways to Book

 [www.lbx-summit.com/take-part/register/](http://www.lbx-summit.com/take-part/register/)

 Tel: +1 617 455 4188

 Email: [info@hansonwade.com](mailto:info@hansonwade.com)



**DISCOVER** how pioneering companies are advancing precision oncology by enhancing liquid biopsy technologies across the full spectrum, from early detection to treatment response and monitoring. Dive into discussions on leveraging ctDNA, MRD, and multi-omics to improve patient outcomes and drive new clinical insights.



**BUILD** your expertise in the latest tools, workflows, and innovations shaping liquid biopsy applications. From optimizing biomarker discovery to scaling workflows for clinical adoption, gain insights to refine your approach and support strategic development in precision oncology.



**ENGAGE** with industry leaders, biopharma experts, and academic pioneers in a collaborative environment. Connect with peers across the liquid biopsy ecosystem to explore partnership opportunities that accelerate breakthroughs in cancer diagnostics and patient care.

All prices shown in US dollars. Please visit the website for full pricing options or email [info@hansonwade.com](mailto:info@hansonwade.com)

### Drug Developers & Research Institutes\*\*

Registration is FREE\* if you work for a drug developer, research organization, or academic institution.

\*Please note that credit card details will be taken upon registration, and a nominal fee of \$0.50 charged.

\*\*A drug developer, researcher or academic must have a pipeline candidate and/or work for an academic institution, and must not provide solutions or services for a fee to any other company.

Free access is only granted once approval of eligibility is confirmed. Hanson Wade retain the right to reject or cancel your registration if eligibility criteria are not met, and paid registration will then be required to access the event.

Hanson Wade reserves the right to charge free access guests a non-refundable charge of \$100 if they do not attend the entire event if they fail to give 7 working days' notice of non-attendance.

### Access to Main Conference

**FREE\* - REGISTER YOUR PLACE HERE**

Please note: Workshop attendance is subject to approval & by invitation only. Visit the website for full T&Cs

### Vendor & Solution Providers\*\*\*

#### Standard Pricing

#### On the Door Pricing

\*\*\*Vendors and Solution Providers refer to all employees from CRO, Software, R&D, Diagnostic, or Pre-Clinical Service Provider organizations who partner with, and provide services to, drug developers and/or research organizations.

If you need further clarification, please contact [info@hansonwade.com](mailto:info@hansonwade.com)

\$3,899 (save \$100)

\$3,999

### Team Discounts\*\*\*\*

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5+ Attendees

\*\*\*\*Please note that group discounts are only valid on paid tickets when three or more delegates from one company book and pay at the same time. Group discounts cannot be used in conjunction with any other offer or discount - only one discount may be applied to the current pricing rate.

Contact: [info@hansonwade.com](mailto:info@hansonwade.com)



## Venue

**Hilton La Jolla Torrey Pines**

10950 N Torrey Pines Rd, La Jolla, CA 92037, United States

[www.hilton.com/en/hotels/santphh-hilton-la-jolla-torrey-pines](http://www.hilton.com/en/hotels/santphh-hilton-la-jolla-torrey-pines)

#### TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom